Is Balaxi Pharmaceuticals Ltd (BALAXI) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Balaxi Pharmaceuticals Ltd is a below average quality company .

Is Balaxi Pharmaceuticals Ltd (BALAXI) undervalued or overvalued?

The key valuation ratios of Balaxi Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone .

What is Balaxi Pharmaceuticals Ltd (BALAXI) share price return in the past 10 years?

Data is not available for this company

Is Balaxi Pharmaceuticals Ltd (BALAXI) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Balaxi Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the share price of Balaxi Pharmaceuticals Ltd (BALAXI)?

Company share prices are keep on changing according to the market conditions. The current trading price of Balaxi Pharmaceuticals Ltd (BALAXI) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Balaxi Pharmaceuticals?

The latest standalone P/E ratio of Balaxi Pharmaceuticals as of 01-Jan-1970 is 37.06.

What is the P/B ratio of Balaxi Pharmaceuticals Ltd (BALAXI)?

The latest standalone P/B ratio of Balaxi Pharmaceuticals Ltd (BALAXI) as of 01-Jan-1970 is 1.06.

What is the 52-week high and low of Balaxi Pharmaceuticals Ltd (BALAXI)?

The 52-week high of Balaxi Pharmaceuticals Ltd (BALAXI) is Rs. 0.00 and the 52-week low is Rs. 0.00.

Balaxi Pharmaceuticals Ltd (BALAXI) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Balaxi Pharmaceuticals Ltd (BALAXI)
Brand: Balaxi Pharmaceuticals

Balaxi Pharmaceuticals Ltd (BALAXI) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Key Metrics

Market Cap

₹141 Cr.

P/E Ratio

37.06

Price to Book (P/B)

1.06

Price to Sales (P/S)

2.01

EV/EBITDA

17.43

Return on Capital Employed (ROCE)

5.12%

Current Price

₹0

Return on Equity (ROE)

2.93%

Return on Assets (ROA)

2.19%

Operating Profit Margin

4.3%

Net Profit Margin

5.91%

Gross Profit Margin

9.4%

Book Value per Share

₹24.1

Sales Growth (YoY)

-13.12%

Sales Growth (3 Years)

-15.56%

Operating Profit Growth (1 Year)

-51.21%

Operating Profit Growth (3 Years)

-46.76%

Net Profit Growth (1 Year)

-1.37%

52-Week Low / High

₹0 / 0

Net Profit Growth (3 Years)

-37.38%

Dividend Yield

0.00%

Promoter Holding

65.99%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Balaxi Pharmaceuticals Ltd?

Balaxi Pharmaceuticals Ltd revenue growth is -13.1% for FY-2025 , which is below its 5 year CAGR of 6% , indicating slower growth.

Q.1 Promoter shareholding and pledge status of Balaxi Pharmaceuticals Ltd?

Promoters hold 65.99% of the Balaxi Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Balaxi Pharmaceuticals Ltd vs industry peers?

Balaxi Pharmaceuticals Ltd revenue CAGR is 5.97% , compared to the industry median CAGR of 0% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Balaxi Pharmaceuticals Ltd belong to?

Balaxi Pharmaceuticals Ltd belongs to the Miscellaneous sector, operating specifically within the Trading segment.

Q.1 Stock return of Balaxi Pharmaceuticals Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of -46.43% based on the current price.

DeciZen - make an informed investing decision on Balaxi Pharma.

Based on:

Data

Overall Rating ⓘ
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

3. Price Trend

Balaxi Pharmaceuticals stock performance

Key Ratios

Is Balaxi Pharmaceuticals Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-2.1%	-4.7%	-39.7%	96.2%	58.4%	55.4%	37.1%	28.2%	6.1%	5.1%	-
Value Creation Index ⓘ	-1.2	-1.3	-3.8	5.9	3.2	3.0	1.7	1.0	-0.6	-0.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0.1	0	0	13.6	45.6	86.9	101	108	70.2	61	70
Sales YoY Gr.	-	-100%	NA	NA	235.5%	90.4%	16.6%	6.8%	-35.1%	-13.1%	-
Adj EPS ⓘ	-0.1	-0.1	-0.5	1.3	1.2	2.8	2.6	2.4	0.5	0.3	0.7
YoY Gr.	-	NA	NA	NA	-8.3%	129.5%	-8.9%	-6.7%	-81.1%	-40%	-
BVPS (₹) ⓘ	2.1	1.5	1	2.3	5.6	8.7	11.6	16.1	21.6	23.2	24.1
Adj Net Profit ⓘ	-0.1	-0.2	-0.8	2	6.1	14	12.8	12.1	2.5	1.5	4
Cash Flow from Ops. ⓘ	-0	-0.1	-0.7	-1.5	-14.4	13.5	8.9	-7.1	-1.8	-7.6	-
Debt/CF from Ops. ⓘ	-5.8	0	0	0	0	0.3	0.2	-1.5	-7.6	-4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	120.3%	6%	-15.6%	-13.1%
Adj EPS ⓘ	NA	-26%	-52.7%	-40%
BVPSⓘ	30.8%	32.7%	26%	7.2%
Share Price	-	-46.4%	-64.1%	-60.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-2.5	-6.4	-39.6	79.7	38.6	39.2	25.2	16.2	2.3	1.2	2.9
Op. Profit Mgn % ⓘ	-145.1	0	0	12	19	21.9	17.1	15.6	7.7	4.3	2.9
Net Profit Mgn % ⓘ	-169.2	0	0	14.9	13.4	16.1	12.6	11.2	3.5	2.5	5.4
Debt to Equity ⓘ	0.1	0	0	0	0	0.1	0	0.1	0.1	0.2	-
Working Cap Days ⓘ	1,827	0	0	80	160	173	193	237	423	518	389
Cash Conv. Cycle ⓘ	-338	0	0	39	103	103	108	154	322	432	222

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	0.7	1.7
TTM Sales (₹ Cr.)	70.3	276
BVPS (₹) ⓘ	24.1	43.2
Reserves (₹ Cr.) ⓘ	122	227
P/BV ⓘ	1.06	0.59
PE ⓘ	37.06	14.95

From the Market
52 Week Low / High (₹)	0.00 / 0.00
All Time Low / High (₹)	- / -
Market Cap (₹ Cr.)	141
Equity (₹ Cr.)	11
Face Value (₹)	2
Industry PE ⓘ	25.4

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Balaxi Pharma. - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	0	0	0	14	46	87	101	108	70	61
Operating Expenses ⓘ +	0	0	1	12	37	68	84	91	65	58
Manufacturing Costs	0	0	0	0	0	0	0	0	0	0
Material Costs	0	0	0	10	33	63	77	82	56	51
Employee Cost	0	0	0	1	2	2	3	4	5	5
Other Costs ⓘ	0	0	1	1	2	3	4	5	3	3
Operating Profit ⓘ	-0	-0	-1	2	9	19	17	17	5	3
Operating Profit Margin (%)	-145.0%	-	-	11.5%	18.9%	21.9%	17.1%	15.6%	7.6%	4.3%
Other Income ⓘ +	0	0	0	1	1	2	3	7	2	5
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0	0	0	0	0	0	0	1	2	2
Depreciation ⓘ	0	0	0	0	0	0	0	1	1	0
Profit Before Tax ⓘ	-0	-0	-1	2	9	21	20	22	6	5
Tax ⓘ	-0	0	0	0	3	5	5	6	2	2
Profit After Tax	-0	-0	-1	2	6	15	15	16	4	4
PAT Margin (%)	-169.0%	-	-	14.5%	14.2%	17.4%	14.5%	15.0%	5.2%	5.9%
Adjusted EPS (₹)	-0.1	-0.1	-0.5	1.3	1.3	3.0	2.9	3.2	0.7	0.7
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	3%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	3	2	2	4	28	43	58	82	118	128
Share Capital ⓘ	3	3	3	3	10	10	10	10	11	11
Reserves ⓘ	0	-1	-1	0	18	33	48	72	107	117
Debt +	0	0	0	0	0	4	2	11	14	30
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	4	2	11	14	30
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0	0	0	2	7	17	16	17	12	9
Others Liabilities ⓘ	0	0	0	1	3	6	6	20	10	7
Total Liabilities ⓘ	4	2	2	6	38	69	82	130	154	174
Fixed Assets
Net Fixed Assets ⓘ +	0	0	0	0	0	1	2	8	7	7
Gross Block	0	0	0	0	0	1	3	9	8	7
Accumulated Depreciation	0	0	0	0	0	0	0	1	1	0
CWIP ⓘ	0	0	0	0	0	0	1	3	2	22
Investments ⓘ	3	0	0	0	0	20	20	20	20	25
Inventories	0	0	0	0	1	0	0	1	1	0
Trade Receivables	0	0	0	5	31	48	52	78	77	90
Cash Equivalents	0	2	2	0	4	0	1	18	44	29
Others Assets ⓘ	0	0	0	0	2	0	7	2	3	2
Total Assets ⓘ	4	2	2	6	38	69	82	130	154	174

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-0	-0	-1	-2	-14	13	9	-7	-2	-8
PBT ⓘ	-0	-0	-1	2	9	21	20	22	6	5
Adjustment ⓘ	0	0	0	0	0	0	0	1	2	3
Changes in Working Capital ⓘ	0	0	0	-4	-23	-5	-5	-25	-4	-14
Tax Paid ⓘ	0	0	0	-0	-1	-2	-6	-5	-5	-2
Cash Flow From Investing Activity ⓘ +	0	3	-0	-0	-0	-20	-7	-2	0	-25
Capex	-0	0	-0	-0	-0	-1	-2	-0	0	-0
Net Investments	0	3	0	0	0	-19	-0	0	-0	-5
Others ⓘ	0	0	0	0	-0	0	-5	-2	1	-20
Cash Flow From Financing Activity ⓘ +	-0	-0	0	0	18	3	-2	26	28	17
Net Proceeds from Shares ⓘ	0	0	0	0	18	0	0	18	26	3
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	-0	0	0	0	-0	-0	-0	-1	-2
Dividend Paid ⓘ	-0	0	0	0	0	0	0	-0	0	0
Others ⓘ	0	-0	0	0	0	4	-2	9	3	16
Net Cash Flow ⓘ	-0	2	-1	-2	3	-3	0	17	26	-15

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-2.52	-6.37	-39.69	77.47	41.07	42.42	29	23.22	3.66	2.93
ROCE (%)	-2.11	-4.69	-39.69	96.22	58.38	55.42	37.14	28.22	6.08	5.12
Asset Turnover Ratio	0.01	0	0	3.49	2.07	1.63	1.34	1.02	0.49	0.37
PAT to CFO Conversion(x)	N/A	N/A	N/A	-1	-2.33	0.87	0.6	-0.44	-0.5	-2
Working Capital Days
Receivable Days	35	0	0	147	147	167	181	220	403	499
Inventory Days	0	0	0	0	7	2	0	5	6	3
Payable Days	0	0	0	39	50	68	77	73	96	77

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Balaxi Pharmaceuticals Ltd FAQs

The current trading price of Balaxi Pharma. on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Balaxi Pharma. stood at ₹141.2 Cr

The latest P/E ratio of Balaxi Pharma. as of 31-Dec-1969 is 37.06.

The latest P/B ratio of Balaxi Pharma. as of 31-Dec-1969 is 1.06.

The 52-week high of Balaxi Pharma. is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Balaxi Pharma. is ₹70.26 ( Cr.) .

About Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Limited is a branded IPR-based pharmaceutical Company focusing on frontier markets, with a vast and growing portfolio of drugs across multiple therapeutic segments. Its markets extend across the continents of Americas, Africa and the Caribbean islands. It is a dynamic and responsible company, with a rich and growing portfolio of branded and generic medicines and consumer products.

Business area of the company

The company is engaged in the business of international wholesale trading of Pharmaceuticals, Builders Hardware and FMCG products

History and Milestones

2003-07

Commenced Pharmaceutcal business by supplying white labeled products to customers in Africa.
Sourcing was from WHO GMP certified plants based in India.

2008-10

Created frontend presence for its Pharmaceutical Business by setting up 1st wholesale depot in Angola in 2008.

2011-13

Started sourcing pharmaceutical from WHO GMP certified manufacturers in China by setting up an office in China in 2011.
Opened first wholesale depot for its ancillary business in Angola.

2014-16

In 2014, the group expanded its pharmaceutical business in Angola by setting up its 12th wholesale depot and a central distribution warehouse.
Made in-roads in Dominican Republic pharmaceutical market, submitted technical dossiers for securing product registrations and opened a central distribution warehouse.

2017-19

Set-up central distribution warehouse in Guatemala marking the entry of Balaxi into its third geography.
Leveraged the vast on-ground infrastructure in Angola by entering branded consumer goods products business in 2019.

2020

Submitted several technical dossiers of Pharmaceutical products in EL Salvador and Honduras for product registrations.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Balaxi Pharmaceuticals Ltd (BALAXI) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating